Introduction
============

The etiology of thyroid eye disease is not well understood, although it is generally presumed to begin in the thyroid since the great majority of patients with Graves' ophthalmopathy (GO) have active thyroid inflammation, ie, a thyroiditis, at the time they develop eye signs.[@b1-opth-11-1337],[@b2-opth-11-1337] A generally accepted hypothesis for the orbital reaction of this complex eye disorder is that there are antigens expressed by thyroid tissue and orbital tissue where they are targeted by autoantibodies and/or sensitized T cells, leading to orbital inflammation.[@b3-opth-11-1337],[@b4-opth-11-1337] This complex eye disorder has been well studied for the thyroid stimulating hormone-receptor (TSHr),[@b5-opth-11-1337]--[@b7-opth-11-1337] but the possible role of the other major thyroid antigens, namely TG and TPO has been largely ignored.[@b8-opth-11-1337]

TG, a glycoprotein homodimer protein made by thyroid follicular cells with a molecular mass of 660 kDa, is the glycoprotein precursor of the thyroid hormones triiodothyronine (T3) and tetraiodothyronine (T4). On hydrolysis it yields only two to four molecules of T3 and T4. The protein contains a 19-amino acid signal peptide followed by 2,748 residues. TG has three functions; namely as a thyroid hormone precursor, storage of iodine, and storage of inactive thyroid hormones.[@b9-opth-11-1337],[@b10-opth-11-1337] The *TG* gene encodes an 8.7 kb mRNA, covers at least 300 kb of genomic DNA, and has 52 exons: 51 introns are as large as 64 kb and within intronic regions are highly conserved intergenic regions which are transposons and repetitive elements. The 5-prime and 3-prime parts of the gene are composed of two evolutionarily different regions. The first 30 kb of DNA encodes 3 kb of the mRNA and the remaining 270 kb encodes 5.7 kb of the mRNA. The *TG* gene maps to chromosome 8q24 region which has been shown to be strongly linked with autoimmune thyroid disease (AITD).[@b11-opth-11-1337]--[@b17-opth-11-1337]

In recent years, we have focused our research on some new ideas concerning the pathogenesis of GO. We showed that levels of serum TG were elevated in patients with Graves' disease (GD) and ophthalmopathy compared to those with GD and no eye signs.[@b18-opth-11-1337] It is possible that its release in the context of thyroid inflammation ("thyroiditis") may lead to orbital inflammation, as has been suggested by us and others in the past.[@b19-opth-11-1337],[@b20-opth-11-1337] Mutations in the *TG* gene cause thyroid dyshormonogenesis,[@b17-opth-11-1337],[@b21-opth-11-1337]--[@b35-opth-11-1337] manifested as goiter, and are associated with moderate to severe congenital hypothyroidism. Polymorphisms in this gene are also associated with susceptibility to AITDs such as GD and Hashimoto's thyroiditis (HT).[@b36-opth-11-1337]--[@b42-opth-11-1337]

The human *TG* gene contains 16,165 single nucleotide polymorphisms (SNPs) present (<http://www.ncbi.nlm.nih.gov/snp/>) -- 800 of *TG* gene SNPs appeared to be highly conserved (<http://ecrbrowser.dcode.org/>). Thirty-two of these SNPs are of clinical significance and ten are pathogenic by virtue of being in germ cells. We hypothesized that these ten germ cell *TG* polymorphisms may be associated with thyroid disorders. We embarked upon genotyping ten evolutionary conserved SNPs within the *TG* gene in a cohort of patients with AITD and controls. We genotyped rs2069566, rs2076739, rs121912646, rs121912647, rs121912648, rs121912649, rs121912650, rs137854433, rs137854434, and rs180195 by MassARRAY SNP analysis using iPLEX technology of SEQUENOM (Agena Bioscience, San Diego, CA, USA); showing SNPs which show strong association with thyroid disorders, paving the way for future in-depth functional studies.

Clinical subjects
=================

Comprehensive demographic, clinical details, and genotypes of SNP rs180195 for patients with GO, Graves' hyperthyroidism (GH), HT, and control subjects without autoimmune diseases have been described in detail[@b43-opth-11-1337] in an earlier publication, summarized in [Table 1](#t1-opth-11-1337){ref-type="table"}. Briefly, partici pants were recruited from outpatients' clinics at Nepean and Royal North Shore Hospitals in New South Wales and the Sir Charles Gairdner Hospital in Western Australia. Previous treatments for hyperthyroidism (with particular reference to radioactive iodine therapy), sex distribution of patients with GD with or without GO, presence or absence of other autoimmune diseases, and presence or absence of eth nic differences in the different groups of patients are shown in [Table 1](#t1-opth-11-1337){ref-type="table"}. Patients' recruitment criteria are described by Walsh et al.[@b44-opth-11-1337] Nepean Blue Mountains Local Health District Human Research Ethics Committee approval was received for the study and informed consent of participating subjects was obtained.

Methods
=======

1\) MassARRAY SNP analysis using iPLEX technology of SEQUENOM has been described in detail in previous publications of this laboratory.[@b43-opth-11-1337],[@b45-opth-11-1337],[@b46-opth-11-1337] 2) Functional analysis: T4, T3, thyroid receptors antibodies (TRAB), TSI, TSHr, TG antibody, and TPO antibody were measured by established radio immunoassay methods in pathology laboratories.

Statistical analyses
====================

Genotypes and allelic frequencies of the *TG* SNP rs180195 in patients with GH, GO, HT, and control subjects were compared using chi-square test or Fisher's exact test following Hardy--Weinberg equilibrium. Correlations were made between levels of the TG protein and parameters of the eye disease, and the presence of the genomic polymorphism of rs180195 with T4, T3, TRAB, TSI, TSHr, TG, and TPO antibody titers, in the three groups, and were analyzed using the Mann--Whitney test of GraphPad Prism Version 3.03 (San Diego, CA, USA). A *P*-value of \<0.05 was taken as significant in all assessments.

Results
=======

We studied the ten potential pathogenic *TG* SNPs occurring in germ cells in a cohort of 529 patients and controls. Only rs180195 was polymorphic. rs180195 SNP is in the promoter region of *TG* gene ([Table 2](#t2-opth-11-1337){ref-type="table"}), and the change in nucleotide is from G \> A; therefore, genotypes are wild-type 189 (GG), heterozygote 238 (GA), and rare homozygote 102 (AA) with major allele frequency of 60% and minor allele frequency of 40%, following Hardy--Weinberg equilibrium. Statistical analysis suggested that rs180195 appeared to be informative and could be further studied for genotypic analysis.

We analyzed SNP rs180195 of *TG* gene across the three genotypes for GO, GH, HT, and control groups. rs180195 ([Table 3](#t3-opth-11-1337){ref-type="table"}) showed significant difference in the pattern of distribution of the genotypes between the different patient groups (*P*=0.038). We were interested to know if alleles G and A would show significant probability and odds ratio in GO, GH, HT, and control groups. Therefore, we performed pair-wise analysis to determine the probability and odds ratio for each allele separately shown in [Table 4](#t4-opth-11-1337){ref-type="table"}. Pair-wise analysis of alleles' frequency distribution in GO, GH, HT vs control groups is shown in [Table 4](#t4-opth-11-1337){ref-type="table"}; rs180195 GO vs control showed odds ratio =0.875, 95% confidence interval =0.591--1.29, *P*=0.504; GH vs control showed odds ratio =0.734, 95% confidence interval =0.530--1.02, *P*=0.062; which did not reach significance; and HT vs control showed odds ratio =0.670, 95% confidence interval =0.481--0.93, *P*=0.018 which was significant.

The difference in genotype frequencies for the wild-type GG ([Table 5](#t5-opth-11-1337){ref-type="table"}) observed in GO vs control was not significant with odds ratio 0.95, 95% confidence interval 0.55--1.64, *P*=0.856 while that for GO vs HT was significant with odds ratio 1.99, 95% confidence interval 1.12--3.52, *P*=0.018; it was also significant for GH vs control subjects with odds ratio 0.60, 95% confidence interval 0.38--0.96, *P*=0.033 and similarly, was significant for HT vs control with odds ratio 0.48, 95% confidence interval 0.29--0.78, *P*=0.003. No significant difference was observed for GH vs HT with odds ratio 1.26, 95% confidence interval 0.76--2.07, *P*=0.367; nor for GO vs GH with odds ratio 1.60, 95% confidence interval 0.90--2.74, *P*=0.104.

A significant difference in frequency for heterozygote GA ([Table 6](#t6-opth-11-1337){ref-type="table"}) was observed for GO vs HT with odds ratio 0.48, 95% confidence interval 0.27--0.84, *P*=0.010 and HT vs control with odds ratio 1.76, 95% confidence interval 1.10--2.80, *P*=0.017, but not for GO vs GH with odds ratio 0.59, 95% confidence interval 0.34--1.02, *P*=0.060.

No difference in frequency for homozygote AA ([Table 7](#t7-opth-11-1337){ref-type="table"}) was observed for GO vs control with odds ratio 1.38, 95% confidence interval 0.75--2.72, *P*=0.346 or GH vs control with odds ratio 1.22, confidence interval 0.68--2.18, *P*=0.501 or HT vs control with odds ratio 1.20, confidence interval 0.66--2.17, *P*=0.552. Wild-type and heterozygote genotypic changes were most significant in HT patients.

We measured the serum levels of TSH, free T4 (FT4), TPO antibody, TG antibody, and the age at the onset of disease in each of the wild-type, heterozygote and rare homozygote genotypes ([Figure 1A--E](#f1-opth-11-1337){ref-type="fig"}). There was a significant difference in levels of TSH between the wild-type GG and heterozygote GA genotypes of *TG* (*P*=0.037) but the difference in levels of TSH between wild-type and rare homozygote AA genotype (*P*=0.065) was not significant. There were no differences in levels of TPO antibodies, FT4, TG antibodies or the age at the onset of disease between wild-type GG and heterozygote GA or wild-type GG and rare homozygote AA.

Levels of the TG protein in the heterozygote GA genotype showed a negative correlation with FT4 (Spearman *r*=-0.695, confidence interval -0.899 to -0.244, *P*=0.0058). Finally, we showed there is a positive correlation between the levels of TG protein and the levels of TSH (Spearman *r*=0.874, *P*=0.007) and a negative correlation with FT4 (Spearman *r*=-0.718, *P*=0.058) in wild-type GG genotype ([Table 8](#t8-opth-11-1337){ref-type="table"}).

Discussion
==========

rs180195 SNP was previously identified by Stefan et al,[@b40-opth-11-1337] independently of us. They showed that this *TG* SNP predisposes to AITDs. However, this is the first study to explore the association between *TG* SNPs and HT. We showed that there was a significant difference in the distribution of major allele (G) vs minor allele (A) in patients with HT. In HT, the wild-type (GG) genotype was less common. In this study we showed that the genotypes homozygous AA and heterozygous GA rs180195 SNP in the promoter of the *TG* gene were more associated with thyroid autoimmunity than the wild-type (GG) polymorphism.

rs180195 is located in the promoter region of the *TG* gene, identified previously by a series of studies[@b40-opth-11-1337],[@b47-opth-11-1337]--[@b49-opth-11-1337] to be a *cis*-regulatory element -- a binding site for IRF-1. In thyroid cells activation of transcription by INF-α takes place through binding of IRF-1 to the rs180195 SNP, which results in induction of the *TG* gene which may influence development of AITD. Stefan et al[@b40-opth-11-1337] showed that the changes in nucleotides in the promoter region of the *TG* gene modified a binding site for IRF-1, a major interferon-induced transcription factor. The same group showed that the polymorphism 1623 A/G SNP (rs180195) increased transcription of the *TG* gene through a genetic/epigenetic mechanism, which we postulate could lead to the development of AITD. These findings support the notion that the thyroid and orbital disorders are not part of the same disease, ie, "Graves' disease", "Hashimoto's disease", but separate autoimmune disorders.

In previous publications[@b43-opth-11-1337],[@b45-opth-11-1337],[@b46-opth-11-1337] we suggested that *CASQ1* gene SNPs rs3838216, rs74123279, and rs2275703 are possible genetic markers for GO and HT, in addition to those that are already known. They are potentially pathogenic genetic markers for the eye muscle component of GO. However, pathogenic manifestations of *CASQ1* SNP could be secondary to a primary target gene such as the *TG* gene. The protein product TG has three important functions; namely as a thyroid hormone precursor, storage site for iodine, and a storage site for inactive thyroid hormones. A small genetic variation in this vital gene would be expected to result in profound effects on the function of the TG protein. Recently, Yin et al,[@b50-opth-11-1337] found no difference in HLA, CTLA4, IL23R or TSHr genotype in GD patients with or without GO, but they did not examine the *TG* promoter SNP.

The main thyroid antigens are: TPO in the follicular cell membrane, TG in the colloid and the TSHr in the thyroid follicular cell membranes. TSHr antibody is associated with hyperthyroidism while serum antibodies against TPO and TG are markers for the thyroid autoimmune processes of HT and GD. In our previous study we showed there was not a significant relationship between ophthalmopathy and these thyroid antibodies in patients with GD, HT or transient (sub-acute, silent, post-partum) thyroiditis.[@b18-opth-11-1337]

In HT patients, at allelic level the A polymorphisms occurred more commonly than the G polymorphism in HT than in controls, in GH than controls, and more commonly in HT than in GO. In HT and GH patients compared with controls, wild-type GG genotypic level showed significant probability with low odds ratio for both groups. Interestingly, when we compared wild-type GG genotype of GO vs wild-type GG genotype of HT, a significantly high probability with high odds ratio was observed, which possibly indicates that there are more common characteristics between these two diseases. It is possible that GO is a separate disease from AITD. A similar picture was observed with the heterozygote genotype GA of 180195 SNP for GO vs HT and in contrast to wild-type genotype, heterozygote genotype of HT vs control showed significant prevalence with high odds ratio ([Table 6](#t6-opth-11-1337){ref-type="table"}).

To demonstrate a functional role of rs180195, we measured levels of each of these parameters in wild-type GG, heterozygote GA and rare homozygote AA genotypes. A significant difference in TSH levels was observed between the wild-type and heterozygote genotype. In the wild-type genotype in HT patients there is a significant positive correlation between TSH and TG levels, indicating TSH as a primary stimulant for thyroid cells and subsequent effects of TG synthesis and function, and negative correlation with FT4. In heterozygote genotypes in HT patients, a significant negative correlation was observed between FT4 and TG indicating that with lower levels of TG, there will be lower levels of thyroid hormones in HT patients.

Conclusion
==========

We identified rs180195 *TG* gene polymorphisms in a panel of *TG* SNPs and showed that the wild-type and heterozy-gote genotypes of *TG* are significantly associated with HT and GH patients, ie, patients with thyroid autoimmunity. This polymorphism appears not to be associated with GO, raising the possibility that the thyroid and orbital disorders are not part of the same disease, ie, "Graves' disease" or "Hashimoto's disease". In future studies, a promoter construct of this polymorphism could be used to study the effect of INF-α. Panels of candidate drugs could be used to control the transcription and translation of the *TG* gene in order to characterize the detailed mechanisms of the action of TG in HT and GH in AITD.
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![The levels of TSH, TPO AB, FT4, TG AB, and age measured in wild-type (GG), heterozygote (GA) and rare homozygote (AA) genotypes.\
**Notes:** (**A**--**E**)rs180195 polymorphism in promoter of *TG* gene conceivably, regulates transcription activity of *TG* gene and possibly translation of TG protein -- this effect can be manifested in levels of TSH, TPO, T4, TG, and age at the onset of disease. As reflection of function of TG, we measured levels of each of these parameters in wild-type, heterozygote, and rare homozygote genotypes. \*Significant difference in TSH levels was observed between the wild-type and heterozygote genotype (**A**).\
**Abbreviations:** AB, antibody; TSH, thyroid stimulating hormone; T4, tetraiodothyronine; FT4, free tetraiodothyronine.](opth-11-1337Fig1){#f1-opth-11-1337}

###### 

Demographics, clinical details of patients with thyroid autoimmunity and control subjects without autoimmune disease

  ---------------------------------------------------------------------------------------------------------------------------------------
  Control                                 Graves ophthalmopathy   Graves hyperthyroidism   Hashimoto's thyroiditis
  --------------------------------------- ----------------------- ------------------------ ----------------------------------------------
  Age: 35.7±12.8                          Age: 52.4±14.6          Age: 48.7±15.8           Age: 51.8±15.3

  (N=148 28%)                             (N=82, 15.5%)           (N=156, 29.5%)           (N=143, 27%)

  **Clinical parameter**                                                                   

  Age at diagnosis                        43±14 (N=66)            40±16 (N=116)            39±17 (N=99)

  Other autoimmune disorders              7 (41%)                 11 (7%)                  17 (15%)

  Family history of thyroid disorders     24 (66%)                77 (54%)                 57 (56%)

  Isotope scan                            21 (40%)                52 (71%)                 

  Goiter diffuse with 1--3 nodules        23 (38%)                29 (47%)                 

  1 nodule                                10 (29%)                19 (27%)                 49 (47%)

  2 nodules                               15 (44%)                39 (56%)                 55 (53%)

  Medication                              51 (60%)                88 (61%)                 107 (92%)

  Radioactive iodine treatment            12 (14%)                21 (14%)                 

  Surgery                                 22 (26%)                36 (25%)                 

  TRAB                                    46.4±132 (N=30)         65.5±160 (N=37)          

  TPO (KIU/L)                             136±106 (N=6)           752±876 (N=10)           904±899 (N=62)

  FT4 at diagnosis (pmol/L)               37.7±23.7 (N=40)        45.2±27.5 (N=74)         12.2±6.1 (N=47)

  FT3 at diagnosis (pmol/L)               17.1±11.9 (N=32)        35.8±124 (N=51)          17.3±33.2 (N=6)

  TSH (mu/L)                                                                               25.39±41.06\
                                                                                           95% confidence interval (16.26--34.53, N=80)

  Highest TSH (mu/L)                                                                       25.26±28.28,\
                                                                                           95% confidence interval (14.07--36.44, N=27)

  TG AB (KIU/L)                                                                            169±286 (N=35)

  Diagnosis \<12/12 post-partum                                                            N=20

  Hashitoxicosis                                                                           N=10

  Hashimoto's did not require treatment                                                    N=6

  Non-European                            N=7                     N=32                     N=7

  Male                                    N=12                    N=30                     N=12

  Female                                  N=62                    N=101                    N=84
  ---------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Age of population expressed as mean years ± standard deviation. Number of patients expressed as N, % of total population.

**Abbreviations:** AB, antibody; TRAB, thyroid receptors antibodies; TgAB, thyroglobulin antibodies; TPO, thyroid peroxidase; TSH, thyroid stimulating hormone; FT4, free tetraiodothyronine; FT3, free triiodothyronine.

###### 

Characteristics of rs180195 informative polymorphism identified in *TG* gene

  --------------------------------------------------------------------------------------------------------------------------------------------------
  SNP        SNP position   Alleles   Ancestral allele   Gene(s)   Role       Amino acid change   Amino acid position   SNP relative to chromosome
  ---------- -------------- --------- ------------------ --------- ---------- ------------------- --------------------- ----------------------------
  rs180195   Chr 8\         A/G       G                  TG        Promoter   −                   −                     \+
             132865378                                                                                                  

  --------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Forward or plus (+) strand of DNA 5′\-\-\--3′ is indicated with "+".

**Abbreviations:** SNP, single nucleotide polymorphism; Chr, chromosome.

###### 

Genotype of *TG* rs180195 SNP distribution in patients with autoimmune thyroid disease with and without ophthalmopathy and controls

  Patient group   Wild-type GG   Heterozygote GH   Homozygote AA   Total       MAF   *χ*^2^   *P*-value
  --------------- -------------- ----------------- --------------- ----------- ----- -------- -----------
                  Number %       Number %          Number %        Number %                   
  GO              35 (43)        29 (35)           18 (22)         82 (100)    40%            
  GH              50 (32)        75 (48)           31 (20)         156 (100)   44%            
  HT              39 (27)        76 (53)           28 (20)         143 (100)   46%            
  Control         65 (44)        58 (39)           25 (17)         148 (100)   36%            
  Total           189 (36)       238 (45)          102 (19)        529 (100)         13.36    0.038

**Note:** Number of patients expressed as % of each population.

**Abbreviations:** SNP, single nucleotide polymorphism; GO, Graves' ophthalmopathy; GH, Graves' hyperthyroidism; HT, Hashimoto's thyroiditis; MAF, minor allele frequency.

###### 

Major and minor allele distribution of *TG* rs180195 SNP in patients with autoimmune thyroid disease with and without ophthalmopathy and controls

  Patient group   Number of major alleles G   Number of minor alleles A   *χ*^2^   Odds ratio (95% confidence interval)   *P*-value
  --------------- --------------------------- --------------------------- -------- -------------------------------------- -----------
  GO              99                          65                          0.805    1.19                                   0.370
  GH              175                         137                                  (0.812--1.75)                          
  GO              99                          65                          0.44     0.875                                  0.504
  Control         188                         108                                  (0.591--1.29)                          
  GH              175                         137                         3.48     0.734                                  0.062
  Control         188                         108                                  (0.530--1.02)                          
  HT              154                         132                         5.61     0.670                                  **0.018**
  Control         188                         108                                  (0.481--0.93)                          
  GH              175                         137                         0.303    1.09                                   0.582
  HT              154                         132                                  (0.793--1.51)                          
  GO              99                          65                          1.30     1.19                                   0.180
  HT              154                         132                                  (0.884--1.93)                          

**Note:** The significant *P*-value is highlighted in bold.

**Abbreviations:** GO, Graves' ophthalmopathy; GH, Graves' hyperthyroidism; HT, Hashimoto's thyroiditis.

###### 

Wild-type genotype of TG rs180195 SNP distribution in patients with autoimmune thyroid disease with and without ophthalmopathy, and controls

  Patient group   Wild-type GG   Variant GA + AA   *χ*^2^   Odds ratio (95% confidence interval)   *P*-value
  --------------- -------------- ----------------- -------- -------------------------------------- -----------
                  Number (%)     Number (%)                                                        
  GO              35 (15)        47 (20)           2.65     1.60                                   0.104
  GH              50 (21)        106 (44)                   (0.90--2.74)                           
  GO              35 (15)        47 (21)           0.033    0.95                                   0.856
  Control         65 (28)        83 (36)                    (0.55--1.64)                           
  GO              35 (16)        47 (21)           5.61     1.99                                   **0.018**
  HT              39 (17)        104 (46)                   (1.12--3.52)                           
  GH              50 (17)        106 (35)          4.55     0.60                                   **0.033**
  Control         65 (21)        83 (27)                    (0.38--0.96)                           
  HT              39 (13)        104 (36)          8.77     0.48                                   **0.003**
  Control         65 (22)        83 (29)                    (0.29--0.78)                           
  GH              50 (17)        106 (35)          0.82     1.26                                   0.367
  HT              39 (13)        104 (35)                   (0.76--2.07)                           

**Notes:** Number of patients expressed as % of total population of each pair. The significant *P*-values are highlighted in bold.

**Abbreviations:** SNP, single nucleotide polymorphism; GO, Graves' ophthalmopathy; GH, Graves' hyperthyroidism; HT, Hashimoto's thyroiditis.

###### 

Heterozygous genotype of *TG* rs180195 SNP distribution in patients with autoimmune thyroid disease with and without ophthalmopathy, and controls

  Patient group   Heterozygote GA   Variant GG + AA   *χ*^2^   Odds ratio (95% confidence interval)   *P*-value
  --------------- ----------------- ----------------- -------- -------------------------------------- -----------
                  Number (%)        Number (%)                                                        
  GO              29 (12)           53 (22)           3.53     0.59                                   0.060
  GH              75 (32)           81 (34)                    (0.34--1.02)                           
  GO              29 (12)           58 (25)           0.81     0.78                                   0.369
  Control         58 (25)           90 (38)                    (0.44--1.35)                           
  GO              29 (13)           53 (23)           6.62     0.48                                   **0.010**
  HT              76 (34)           67 (30)                    (0.27--0.84)                           
  GH              75 (25)           81 (26)           2.44     1.44                                   0.118
  Control         58 (19)           90 (30)                    (0.91--2.27)                           
  HT              76 (26)           67 (23)           5.70     1.76                                   **0.017**
  Control         58 (20)           90 (31)                    (1.10--2.80)                           
  GH              75 (25)           81 (27)           0.77     0.82                                   0.381
  HT              76 (26)           67 (22)                    (0.52--1.29)                           

**Notes:** *P*=\<0.1 indicates a tendency toward significance. Number of patients expressed as % of total population of each pair. The significant *P*-values are highlighted in bold.

**Abbreviations:** SNP, single nucleotide polymorphism; GO, Graves' ophthalmopathy; GH, Graves' hyperthyroidism; HT, Hashimoto's thyroiditis.

###### 

Homozygous genotype of *TG* rs180195 SNP distribution in patients with autoimmune thyroid disease with and without ophthalmopathy, and controls

  Patient group   Homozygote AA   Variant GG + GA   *χ*^2^   Odds ratio (95% confidence interval)   *P*-value
  --------------- --------------- ----------------- -------- -------------------------------------- -----------
                  Number (%)      Number (%)                                                        
  GO              18 (7)          64 (27)           0.14     1.134                                  0.706
  GH              31 (13)         125 (53)                   (0.59--2.18)                           
  GO              18 (8)          64 (28)           0.89     1.38                                   0.346
  Control         25 (11)         123 (53)                   (0.75--2.72)                           
  GO              18 (8)          64 (28)           0.18     1.15                                   0.671
  HT              28 (13)         115 (51)                   (0.59--2.25)                           
  GH              31 (10)         125 (41)          0.45     1.22                                   0.501
  Control         25 (8)          123 (41)                   (0.68--2.18)                           
  HT              28 (10)         115 (39)          0.35     1.20                                   0.552
  Control         25 (9)          123 (42)                   (0.66--2.17)                           
  GH              31 (10)         125 (42)          0.004    1.02                                   0.950
  HT              28 (9)          115 (39)                   (0.58--1.80)                           

**Notes:** *P*=\<0.1 indicates a tendency toward significance. Number of patients expressed as % of total population of each pair.

**Abbreviations:** SNP, single nucleotide polymorphism; GO, Graves' ophthalmopathy; GH, Graves' hyperthyroidism; HT, Hashimoto's thyroiditis.

###### 

Assessments of correlation between levels of TG protein and other biochemical parameters affected by TG protein in wild-type GG and heterozygote GA genotypes of HT patients

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Correlation analysis      TSH wild-type\                                     TPO wild-type\   FT4 wild-type\                                   Age wild-type\   TSH heterozygote\   TPO heterozygote\   FT4 heterozygote\                                  Age heterozygote\
                            GG                                                 GG               GG                                               GG               GA                  GA                  GA                                                 GA
  ------------------------- -------------------------------------------------- ---------------- ------------------------------------------------ ---------------- ------------------- ------------------- -------------------------------------------------- -------------------
  Number of patients        8                                                  8                8                                                8                14                  14                  14                                                 14

  Spearman *r*              0.874                                              0.089            −0.718                                           −0.359           −0.251              0.0369              −0.695                                             0.217

  95% confidence interval                                                                                                                                         −0.699--0.337       −0.516--0.568       −0.899--0.244                                      −0.369--0.680

  *P*-value                 0.007                                              0.840            0.0576                                           0.389            0.385               0.900               0.006                                              0.454

  *P*-value summary         [\*\*](#tfn16-opth-11-1337){ref-type="table-fn"}                    [\*](#tfn15-opth-11-1337){ref-type="table-fn"}                                                            [\*\*](#tfn16-opth-11-1337){ref-type="table-fn"}   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*\<0.5--0.01 indicates a tendency towards significance.

*P*\<0.05--0.001.

**Abbreviations:** TSH, thyroid stimulating hormone; FT4, free tetraiodothyronine.
